Provided by Tiger Trade Technology Pte. Ltd.

Corcept Therapeutics

35.97
+0.27000.76%
Post-market: 35.970.00000.00%17:58 EST
Volume:1.13M
Turnover:40.43M
Market Cap:3.83B
PE:43.87
High:36.27
Open:34.56
Low:34.34
Close:35.70
52wk High:117.33
52wk Low:28.66
Shares:106.37M
Float Shares:86.88M
Volume Ratio:0.59
T/O Rate:1.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.8200
EPS(LYR):0.8200
ROE:15.01%
ROA:3.34%
PB:5.91
PE(LYR):43.87

Loading ...

Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer

THOMSON REUTERS
·
Jan 22

Analysts’ Top Healthcare Picks: Natera (NTRA), Corcept Therapeutics (CORT)

TIPRANKS
·
Jan 22

Top Insider-Owned Growth Companies In January 2026

Simply Wall St.
·
Jan 21

Piper Sandler Keeps Their Buy Rating on Corcept Therapeutics (CORT)

TIPRANKS
·
Jan 20

Insider-Favored Growth Stocks To Consider In January 2026

Simply Wall St.
·
Jan 20

A Look At Corcept Therapeutics (CORT) Valuation After The FDA Complete Response Letter On Relacorilant

Simply Wall St.
·
Jan 13

Top Growth Companies With Insider Ownership In January 2026

Simply Wall St.
·
Jan 09

Chief Development Officer William Guyer Reports Disposal of Corcept Therapeutics Common Shares

Reuters
·
Jan 09

Crinetics Experimental Pill Slashes Hormones In Rare Adrenal Disease Trial

Benzinga_recent_news
·
Jan 06

Benzinga Bulls And Bears: Nike, SpaceX, Ultragenyx — And Chinese Tech Stocks Slide

Benzinga_recent_news
·
Jan 03

Insider Picks For High Growth In January 2026

Simply Wall St.
·
Jan 03

Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jan 02

January 2026's Leading Growth Companies With Insider Influence

Simply Wall St.
·
Jan 02

U.S. RESEARCH ROUNDUP-Axsome Therapeutics, Block, Terawulf

Reuters
·
Jan 02

Top Growth Companies With High Insider Ownership In January 2026

Simply Wall St.
·
Jan 01

US Equity Markets Fall on Final Day of 2025 Amid Broad Market Decline

MT Newswires Live
·
Jan 01

Corcept Therapeutics Down Over 48%, on Pace for Largest Percent Decrease Since May 2014 -- Data Talk

Dow Jones
·
Jan 01

Wolfe Research Downgrades Corcept Therapeutics to Underperform from Peer Perform, Price Target is $30

MT Newswires Live
·
Dec 31, 2025

US FDA Declines to Approve Corcept's Drug for Rare Hormonal Disorder

Reuters
·
Dec 31, 2025

Corcept Therapeutics (CORT.US) Plummets Over 46% Following FDA Rejection of New Drug Application

Stock News
·
Dec 31, 2025